Last reviewed · How we verify
VX-118
At a glance
| Generic name | VX-118 |
|---|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (PHASE1)
- A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VX-118 CI brief — competitive landscape report
- VX-118 updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI